在固体剂型的增材制造过程中控制的API结晶,用于灵活的综合制药制造
Aliou Mbodji1, Kelitsha Mulero Cruz2, Andrea Arroyo Gómez3
1Crystallization Design Institute, Molecular Sciences Research Center, University of Puerto Rico, San Juan, PR 00926, United States.
International journal of pharmaceutics
|September 27, 2025
概括
这项研究引入了增材制造,通过将液体溶液分发到囊中来制造固体剂型. 这种新的工艺产生了与商业药物产品质量相匹配的晶体固体分散.
科学领域:
- 制药科学 制药科学
- 材料科学 材料科学 材料科学
- 化学工程是化学工程的重要组成部分.
背景情况:
- 传统的固体剂型制造涉及复杂的单元操作和处理固体的挑战.
- 液体配送提供了一个潜在的替代方案来克服制造复杂性.
- 增材制造为灵活和强化制药生产提供了机会.
研究的目的:
- 通过添加剂制造来探索液体配剂,以创建口服固体剂型.
- 开发一种强大的工艺来产生晶体固体分散.
- 为了证明药物配方的通用化方法.
主要方法:
- 将药物物质,溶剂和聚合物溶液分发到囊载体中.
- 使用受控的溶剂蒸发来诱导聚合物矩阵内的结晶.
- 评估关键过程参数 (温度,度,蒸发率,溶剂选择) 和性能指标.
主要成果:
- 在聚乙烯糖醇中成功生成了种族性莫达菲尼尔 (MOD) 的晶体固体分散.
- 实现了MOD所需的多态形态形式I.
- 制造的固体分散物满足了与商用莫达菲尼尔片 (Provigil®) 相比的质量属性.
结论:
- 通过液体配方进行增材制造为固体剂型生产提供了灵活的方法.
- 开发的过程可用于各种药物物质-聚合物-溶剂系统,用于晶体和无形固体分散.
- 这种方法支持工艺强化和个性化医疗和使用点制造的潜在应用.
相关概念视频
Factors Influencing Drug Absorption: Pharmaceutical Parameters
403
Solid dosage forms such as tablets and capsules undergo rigorous manufacturing processes to ensure stability and effectiveness. Their dissolution and absorption properties are influenced significantly by the choice of excipients (inactive ingredients that serve various roles in the formulation), and the methodology applied during production. The manufacturing parameters, such as compression force and granulation techniques, significantly affect dissolution rates. Elevated compression forces...
403
Factors Affecting Dissolution: Polymorphism, Amorphism and Pseudopolymorphism
673
Polymorphism refers to the existence of a drug substance in multiple crystalline forms, known as polymorphs. Recently, this term has been expanded to include solvates (forms containing a solvent), amorphous forms (non-crystalline forms), and desolvated solvates (forms from which the solvent has been removed).
Some polymorphic crystals possess lower aqueous solubility than their amorphous counterparts, leading to incomplete absorption. For instance, the oral suspension of Chloramphenicol, which...
Some polymorphic crystals possess lower aqueous solubility than their amorphous counterparts, leading to incomplete absorption. For instance, the oral suspension of Chloramphenicol, which...
673
Crystal Growth: Principles of Crystallization
4.8K
Crystallization is a phase transformation process in which crystals are precipitated from a supersaturated solution or formed from other sources. During crystallization, atoms or molecules arrange themselves into a well-defined, rigid crystal lattice to minimize energy.
Initiating crystallization involves manipulating the concentration of the solute and the temperature of the solution. Since crystal growth occurs when the ratio of concentration and solubility of the solute in the solvent...
Initiating crystallization involves manipulating the concentration of the solute and the temperature of the solution. Since crystal growth occurs when the ratio of concentration and solubility of the solute in the solvent...
4.8K
Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules
307
Bioequivalence in generic drugs, such as tablets and capsules, refers to their pharmaceutical equivalence to the brand-name counterparts. However, for therapeutic equivalence, manufacturers must also consider physical attributes like size, shape, and weight (FDA Guidance for Industry, December 2003). Discrepancies in these aspects could impact patient compliance and cause medication errors. For instance, swallowing difficulties, often experienced with larger tablets or capsules, can lead to...
307
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
151
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
151
Polymer Classification: Crystallinity
3.8K
Unlike ionic or small covalent molecules, polymers do not form crystalline solids due to the diffusion limitations of their long-chain structures. However, polymers contain microscopic crystalline domains separated by amorphous domains.
Crystalline domains are the regions where polymer chains are aligned in an orderly manner and held together in proximity by intermolecular forces. For example, chains in the crystalline domains of polyethylene and nylon are bound together by van der Waals...
Crystalline domains are the regions where polymer chains are aligned in an orderly manner and held together in proximity by intermolecular forces. For example, chains in the crystalline domains of polyethylene and nylon are bound together by van der Waals...
3.8K


